CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 494 enrolled
Drug / intervention
Metformin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02049814
NCT02049814Phase 4Completed

A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin

Takeda·interventional·Posted Jan 30, 2014·Updated Mar 13, 2019

In Brief

A Phase 4 clinical trial evaluating Metformin, Voglibose, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 494 participants across 18 sites.

Detailed Summary

The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 30, 2014
Enrollment StartMay 9, 2014
Primary CompletionJun 1, 2016
Study CompletionJun 28, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.4 years ago

Interventions

Metformindrug

Metformin tablets

Voglibosedrug

Voglibose tablets

Acarbosedrug

Acarbose tablets